Neurodegenerative Disease Articles & Analysis

Vybion announces the issue by the USPTO of Patent No. 9932394 entitled, "Single Chain Intrabodies that Alter Huntingtin Mutant Degradation". Issued claims cover composition of matter as well as both the Huntingtin and Tau protein targets with the potential for treatment of both Huntington's and Alzheimer's diseases. A continuation on the remaining methods claims has been filed. This patent ...

By Vybion

MODAG today announced the appointment of Johannes Levin, M.D., as Chief Medical Officer (CMO). Dr. Levin brings with him over ten years of experience in the field of movement disorders, particularly in atypical Parkinsonism such as Multiple System Atrophy (MSA), along with a strong scientific background in protein aggregation. He recently led a clinical MSA study with Prof. Dr. Armin Giese, CSO ...

By MODAG GmbH

NEW YORK, December 13, 2021 — Woolsey Pharmaceuticals, a clinical-stage company developing treatments for neurodegenerative diseases, today announced it commenced a study of BRAVYL in Amyoptrophic Lateral Sclerosis (ALS) patients. ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. ALS is part of a wider group of disorders known as ...

By Woolsey Pharmaceuticals, Inc.

Vybion, Inc. is pleased to announce that its patent application covering methods of use and composition for INT41 Gene Therapy received Track I status from the USPTO. The INT41 patent application covers several neurodegenerative diseases in addition to Huntington's Disease including Spinal Cerebellar Ataxia, Spinal Muscular Atrophy, and Alzheimer's. "Vybion is pleased to receive Track I status on ...

By Vybion

Kurve Therapeutics, a next-generation medtech innovator focused on developing treatments for neurodegenerative diseases, announced it has filed a Form 1-A preliminary offering circular with the U.S. Securities and Exchange Commission (SEC) for a $50 million funding round [kurvetx.com/offering-circular]. Investment opportunities are now open to public investors for offers starting at $580 for 100 ...

By Kurve Therapeutics, Inc.

Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that management will present at the H.C. Wainwright Annual Global Investment Conference on Tuesday, September 15, 2020 at 2:00 PM ET. About Axial Biotherapeutics Axial Biotherapeutics is a clinical stage ...

By Axial Therapeutics Inc.

MODAG, a German biotechnology company focused on the development of disease-modifying small molecule therapeutics for neurodegenerative diseases, today announced the clinical trial initiation of, and recruitment for, a first-in-human Phase 1 study of lead candidate, anle138b in healthy volunteers. The compound is initially being developed for the treatment of Multiple System Atrophy (MSA), with ...

By MODAG GmbH

Axial Therapeutics Inc., a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that company management will participate in a fireside chat hosted by LifeSci Capital on Tuesday, November 17, 2020 at 1:00 PM ET. About Axial Therapeutics Axial Therapeutics is a clinical-stage, ...

By Axial Therapeutics Inc.

Axial Therapeutics Inc., a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that company management will present at the virtual Piper Sandler 32 nd Annual Healthcare Conference taking place November 30 – December 3, 2020. The presentation will be available for registered ...

By Axial Therapeutics Inc.

A five-year action plan developed to meet requirements under Section 4 of the Accelerating Access to Critical Therapies for ALS Act. ...

By Virpax Pharmaceuticals

Vybion will present data on how its drug, INT41, alters a critical event in the development of Huntington's disease at the 7th Neurodegenerative Conditions Research & Development Conference in Boston on September 9-10, 2013. INT41 is an Intrabody drug delivered by Gene Therapy that blocks gene dysregulation in Huntington's Disease by neutralizing a toxic fragment of the Huntingtin mutant ...

By Vybion

Altoida, Inc. an AI company pioneering next-generation neurological disease diagnostics, and GN Group, a global leader in intelligent audio solutions, have signed a multi-year strategic partnership to research and develop new digital biomarkers for identifying Mild Cognitive Impairment (MCI). The research will serve as the backbone for new augmented reality tools to help at-risk individuals gain ...

By Altoida, Inc.

Sibylla PPI-FIT technology identifies novel druggable pockets in the intermediate folding states of proteins Sibylla intends to market the PPI-FIT technology platform-as-a-service‚ to the biotechnology and pharmaceutical industries. It also plans to generate its own in-house proprietary pipeline Verona (Italy), May 18th 2021 – Sibylla Biotech announced a research collaboration with ...

By Sibylla Biotech S.p.A.

Regular exercise could help prevent brain damage associated with neurodegenerative diseases like Alzheimer’s, according to research published this month in Elsevier’s journal Brain, Behavior, and Immunity. “Exercise allows the brain to rapidly produce chemicals that prevent damaging inflammation”, said Professor Jean Harry, who led the study at the National Institute of ...

By National Institute of Environmental Health Sciences (NIEHS)

Hillel Bachrach, Jason Camm and Zafrira Avnur join EnClear Therapies Board of Directors -- Investors include 20/20 HealthCare Partners, Amgen Ventures, Peter Thiel, Global Health Sciences (GHS) Fund, Christian Angermayer’s Presight Capital, and Dolby Ventures EnClear Therapies, a life sciences company developing device-based therapies for the treatment of neurodegenerative disease, ...

By EnClear Therapies

NEW YORK, NY – October 1, 2021 – Woolsey Pharmaceuticals announced today that it completed a second round of financing of $19.7 million. Proceeds will fund operations through the completion of Phase 2a clinical studies of BRAVYL for Wandering in Dementia, Progression Supranuclear Palsy, Corticobasal Syndrome, and Amyotrophic Lateral Sclerosis. The Company also announced the ...

By Woolsey Pharmaceuticals, Inc.

Data presented at AAIC demonstrates oral lead product candidate OLX-07010 reduces tau self-association and insoluble tau aggregates Oligomerix to begin clinical testing of OLX-07010 in 2Q22 Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, announced that the Company ...

By Oligomerix, Inc.

Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s and rare neurodegenerative diseases, announced that the Company presented data from a therapeutic study in an animal model of its lead product candidate OLX-07010 at the 14th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference and at the Society for ...

By Oligomerix, Inc.

NEW YORK, NY – January 3, 2021 – Woolsey Pharmaceuticals, a repurposed therapeutics development company announced that the European Medicines Agency’s Committee for Orphan Medicinal Product has issued a positive opinion on the orphan drug application for the Company’s investigational drug, BRAVYL® (oral fasudil), for the treatment of Amyotrophic Lateral Sclerosis ...

By Woolsey Pharmaceuticals, Inc.

Researchers at Saneron CCEL Therapeutics, Inc. of Tampa, Florida, (www.saneron-ccel.com) and the University of South Florida have received a patent relating to a method for obtaining and using umbilical cord blood cells from a donor or patient to provide neural cells for transplantation aimed at repairing a variety of neurodegenerative diseases of the brain and spinal cord, such as ...

By Saneron CCEL Therapeutics, Inc.